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A B S T R A C T
Background
Some women with diabetes in pregnancy are encouraged to express and store colostrum prior to birthing. Following birth, the breastfed
infant may be given the stored colostrum to minimise the use of artificial formula or intravenous dextrose administration if correction
of hypoglycaemia is required. However, findings from observational studies suggest that antenatal breast milk expression may stimulate
labour earlier than expected and increase admissions to special care nurseries for correction of neonatal hypoglycaemia.
Objectives
To evaluate the benefits and harms of the expression and storage of breast milk during late pregnancy by women with diabetes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 June 2014).
Selection criteria
All published and unpublished randomised controlled trials comparing antenatal breast milk expressing with not expressing, by pregnant
women with diabetes (pre-existing or gestational) and a singleton pregnancy.
Data collection and analysis
Two review authors independently evaluated reports identified by the search strategy.
Main results
There were no published or unpublished randomised controlled trials comparing antenatal expressing with not expressing. One
randomised trial is currently underway.
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Authors’ conclusions
There is no high level systematic evidence to inform the safety and efficacy of the practice of expressing and storing breast milk during
pregnancy.
P L A I N L A N G U A G E S U M M A R Y
Breast milk expression during pregnancy by women with diabetes for improving infant outcomes
Babies born to women who have diabetes during pregnancy, either already existing or gestational, are at increased risk of low blood
sugars after birth. This is because the babies have been exposed to higher than usual blood sugar (glucose) levels during the pregnancy
and so have been producing relatively high levels of insulin. Some of these babies require additional breast milk, formula feeds or
transfer to a special care nursery for intravenous fluids to correct the low blood sugar levels.
Some maternity care providers and women propose that expressing and storing colostrum, the initial nutrient-rich breast milk, during
pregnancy, can be given to the baby if they develop low blood sugars after birth. This may help avoid the need for formula feeds if
breastfeeding, intravenous fluids and separation from the mother if the baby has to go to the special care nursery. Although this process
seems logical and is sometimes recommended, two small observational studies have shown that mothers who expressed breast milk
during pregnancy were more likely to have their babies early and more of the babies were cared for in the special care nursery compared
with those whose mothers did not express.
This systematic review sought to identify randomised controlled trials comparing outcomes for women with diabetes who were advised
to express with women not advised to express and store breast milk during pregnancy. The search did not find any completed trials,
although one trial is currently underway.
There is no high level evidence about the potential benefits and harms of the expression and storage of breast milk during pregnancy
by women with diabetes.
B A C K G R O U N D
Description of the condition
Infants born to mothers who have diabetes in pregnancy (ges-
tational or pre-existing) are at increased risk of neonatal hypo-
glycaemia (low blood sugar) compared to other infants (Hanson
1993). This can be explained by their exposure to higher glucose
levels in utero than usual, with subsequent increased insulin se-
cretion. These infants may then need to adjust their insulin se-
cretion to deal with postnatal glucose intake levels. It is for this
reason that, in the first few days of life, many of these infants be-
come hypoglycaemic and will require additional glucose, provided
by intake from breastfeeding or breast milk expressed after birth,
from donor human milk, artificial formula or via an intravenous
infusion.
To avoid this condition developing in infants born to mothers
who have diabetes in pregnancy, a readily available supply of breast
milk from birth would seem to be an attractive option. This is par-
ticularly so in view of the World Health Organization’s (WHO)
recommendation that infants be exclusively breastfed, whether di-
rectly from the breast or as expressed breast milk, for the first six
months, that is, without any supplements, artificial formula or
solid food (WHO 2011).
However, a number of barriers may be identified to successful
initiation of breastfeeding in this group of mothers and their ba-
bies. Colostrum from early breastfeeds in the first hours after birth
would normally provide all the necessary nutrients for infants born
to women without diabetes (WHO 2011). The additional nutri-
tive needs of infants born to women with diabetes may not be suf-
ficiently met by colostrum from early breastfeeds (Hanson 1993).
Additionally, because euglycaemia (normal levels of glucose in the
blood) appears to be an important influence on the onset of lac-
togenesis II (the copious flow of milk within a few days of giving
birth), women with diabetes in pregnancy with hypoglycaemia
or hyperglycaemia may be at increased risk of delaying this pro-
gression (Arthur 1994; Neubauer 1993). Thus, the infant who is
already at increased risk of morbidity related to his/her mother’s
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diabetes, may also be exposed to artificial formula and separation
from the mother if transferred to a nursery facility for intravenous
fluid administration and glucose monitoring.
Further, avoidance of dietary exposure to some proteins found
in cow’s milk and the potential for a stronger immune system in
exclusively breastfed infants may decrease the likelihood of these
children subsequently developing B-cell autoimmunity and Type
1 diabetes (Ip 2007; Newburg 2005; Silverman 1995).
Description of the intervention
Antenatal breast milk expression in women with diabetes has been
proposed as an intervention for building up a supply of colostrum
expressed during pregnancy that can be used if needed after the
birth.
Historically, antenatal breast preparation, including milk expres-
sion, was proposed as a means of minimising breastfeeding prob-
lems in the postnatal period. Chapman 2013a reviewed the evo-
lution of antenatal breast preparation and described three epochs
of trends. Epoch I: antenatal breast preparation, with publications
from 1946 to 1983, described antenatal expressing and discarding
colostrum. The studies byWaller 1946 andBlaikley 1953 involved
having women express and discard colostrum from 20 or 28 weeks
of pregnancy respectively. Overall findings included improved
milk flow postnatally, less breast engorgement, less cracked nipples
and improved exclusivity of breastfeeding to six months for in-
fants of women who had expressed, compared with those who had
not. These findings contrasted with those of Ingleman-Sundberg
1958, who compared outcomes in 656 women who did or did
not express from 20 weeks of pregnancy and reported no differ-
ence in breastfeeding rates and a trend toward increase mastitis
in women who had expressed during pregnancy. Similarly, Brown
1975 reported no differences in nipple trauma or sensitivity for
either breast in three groups of women (total n = 57) who had
used nipple rolling, creams or expressing during pregnancy on one
breast and not the other.
Epoch 2 of the review by Chapman 2013a included publications
from 1986 to 1993 of nipple stimulation, that reported on the
contraction stress test and as a means of ripening the cervix and
augmenting labour (Kavanagh 2005; Langrew 1995). The con-
traction stress test involved nipple stimulation during electronic
fetal heart rate monitoring to determine the fetal response to the
stress of an increase in circulating oxytocin thatmay lead to uterine
contractions (Langrew 1995). Both the release of oxytocin dur-
ing breast or nipple stimulation and the potential for this inter-
vention to influence labour are discussed below under The safety,
effectiveness and acceptability by women of antenatal colostrum
expression.
Chapman 2013a outlined Epoch 3 (2008 to the present) as the
emergence of antenatal breast milk expression for building up
a store of colostrum (although some publications pre-date this
epoch, for example, Clay 2005; Oscroft 2001). This involves
teaching women to hand express colostrum, for example, once or
twice a day for several minutes and collect this in a syringe or cup.
Expressed colostrum can be labelled with the mother’s name and
date of birth, then stored by placing the syringe into a sealed plastic
bag and placing it in the freezer. The woman can then bring the
frozen colostrum with her to the hospital in a cold container when
she is admitted for the birth. Varying amounts of colostrum are
able to be expressed at each episode, for example, Forster 2011a
reported a median of 1.67 mL (range 0.21 to 14.1mL) from 26
women. These women expressed a median of 39.6 mL (range 5
to 310 mL) in total over a period of 14 days (range 4 to 30 days).
Rietveld 2011 reported findings for 10 women with diabetes in
pregnancy, who had been instructed to express twice daily from
34 weeks’ gestation until the birth of the baby. The purpose of
the study was to consider issues of the feasibility of antenatal ex-
pressing, storage and provision of stored colostrum to the infants
if they became hypoglycaemic after birth. Women averaged 53
episodes of expression (range 19 to 80), which they conducted
once or twice daily. The total volume of expressed colostrum av-
eraged 88.5 mL (range 2.8 to 322 mL). The women gave birth
at an average of 38 weeks and five days, with all infants being
born after 37 weeks. One baby had a blood glucose level of 1.7
mmol/L (i.e. hypoglycaemia, although not confirmed by a true
blood glucose (TBG) measurement) and was supplemented with
cows’ milk formula, even though banked colostrum was available.
The hypoglycaemia persisted to the next test prior to feeding (2.4
mmol/L) and the baby received some banked colostrum following
the breast feed.Women reported being satisfied with the process of
expressing and storing colostrum and agreed that this was helpful
with breastfeeding.
A randomised controlled trial of pregnant women (without di-
abetes) antenatal expressing and then discarding the colostrum
was reported by Singh 2009, who tested the hypothesis that this
practice would reduce breastfeeding failures following birth. They
noted that 2% of the 71 participants in the non-expressing group
took over 72 hours from the birth to achieve “full lactation” (un-
defined), compared with none in the expressing group (P < 0.01).
The proposed advantage of antenatal expression and storage of
colostrum is that, following birth, should additional nutrition be
required, this can be given instead of artificial formula (Cox 2006).
A survey of lactation consultants in Australia reported a growing
awareness of antenatal breast milk expression, even when the prac-
tice was not promoted by the individual lactation consultants who
responded to the survey (Chapman 2013b).
The safety, effectiveness and acceptability by
women of antenatal colostrum expression
Women in some parts of the world continue breastfeeding their
child during a subsequent pregnancy, with some evidence of the
safety and effectiveness of this practice for the pregnancy (not
increasing the risk of miscarriage), intrauterine fetal growth or
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concerns about infant growth and morbidity (Avrim 2014; Isihi
2009; Marquis 2003; Merchant 1990; Moscone 1993; Pareja
2012).
Breast or nipple stimulation, including through sexual activity, in
preparation for breastfeeding, to stimulate cervical preparation for
labour, expression of breast milk, or through suckling by the baby,
results in the release of the hormone, oxytocin, which may lead
to uterine contractions (Amico 1986; Bealer 2010; Christensson
1989). This raises the issue of the potential for antenatal colostrum
expression to unintentionally influence the timing of the birth.
Specifically, breast or nipple stimulation may be utilised as ameans
of inducing labour, as reported in a systematic review of six tri-
als (719 women) comparing stimulation with no intervention in
women from 37 weeks of gestation (Kavanagh 2005). The review
reported a significant reduction in the proportion of women not
in labour within 72 hours (62.7% versus 93.6%, risk ratio (RR)
0.67, 95% confidence interval (CI) 0.60 to 0.74). Although these
findings were only significant in women who entered the study
with a favourable cervix (that is, ready for labour), some older ran-
domised trials have demonstrated an improvement in the Bishop’s
score, which gauges cervical preparedness for labour (Damania
1992; Di Lieto 1989; Salmon 1986).
To explore whether expressing colostrum during pregnancy in-
fluenced the timing of labour onset, Soltani 2012 reported out-
comes from a retrospective cohort study of 94 women with dia-
betes who expressed or did not express antenatally. There was a
trend for infants of mothers who had expressed antenatally to be
more likely to be born a week earlier (mean gestation 37.1 weeks,
standard deviation (SD) 2.6) than infants whose mothers had not
undertaken antenatal breast milk expression (mean 38.2 weeks,
SD 2.2), although this did not reach statistical significance (P =
0.06). The clinical, if not the statistical, importance of birthing a
week earlier, albeit still “at term”, or “near term” given the range of
gestation indicated by the standard deviation, warrants consider-
ation when noting the trend for more babies whose mothers had
expressed colostrum antenatally to be admitted to the neonatal
nursery (33% versus 12% in the non-expressing group, P = 0.06)
(Soltani 2012). This concern was supported by findings from the
study by Forster 2011a, which enrolled 43 women with diabetes
in a prospective non-randomised study of antenatal breast milk
expression twice a day for 10 minutes from 36 weeks’ gestation.
Outcomes for this group were compared with those from a retro-
spective audit of 89 women with diabetes who had not expressed
during pregnancy. Forster 2011a reported increased rates of ad-
mission to the special care nursery in the expressing group (RR
1.79, 95% CI 0.94 to 3.33). The wide CI suggests that more par-
ticipants would be required to confirm or refute this concern. The
proportion of these nursery admissions attributed to neonatal hy-
poglycaemia was 64%, compared to 54% in the non-expressing
group. The study by Forster 2011a also reported that five women
experienced uterine tightening or BraxtonHicks contractions after
expressing and did not continue this activity. Forty per cent of in-
fants of women who had expressed milk received artificial formula
within 24 hours of birth compared with 56% of the comparison
group (RR 0.72, 95% CI 0.48 to 1.09).
Forster 2011a, asked women to record their blood glucose levels
after the first three episodes of expressing. The groupmedian blood
glucose levels were normal, although two women reported a blood
glucose of < 3.5 mmol/L after their first episode of expressing.
This potential for hypoglycaemia warrants further consideration
in this group of women.
Women have identified positive aspects of their experiences with
antenatal expressing. For example, in the study by Forster 2011a,
30% of the women who had expressed antenatally noted that
they had increased confidence and felt more prepared for postna-
tal breastfeeding. Women also noted their positive feelings about
having a ready supply of colostrum and learning to express. Some
women found antenatal expressing difficult (31%) and reported
sore breasts/nipples (19%).
How the intervention might work
The storage of expressed colostrum to be given (if required) in
addition to breast milk obtained directly from the breast or ex-
pressed after birth, may avert the need for artificial formula or
intravenous fluid administration if correction of hypoglycaemia is
required. Some clinical guidelines (e.g. NICE 2008) recommend
close monitoring of the baby’s blood sugar level in the postnatal
period, with the mother and baby remaining together for care.
Should the infant become hypoglycaemic (often defined as a true
blood glucose (TBG) of less than 2.6 mmol/L), a prescribed series
of escalating interventions is followed, which may include separa-
tion of the baby from the mother through admission to a special
or intensive care nursery if an additional feed of breast milk or for-
mula does not result in euglycaemia within an hour, or by the time
of the next feed (NETS 2009). Consequently, there are substantial
economic and social costs attributable to such admissions and to
separation of the mother and her baby (Argus 2009; Figueiredo
2009). The limited expenses involved in educating women to ex-
press and the provision of sterile containers and freezer storage
would be likely to be considerably less than the costs of specialised
nursery admission and treatment.
Why it is important to do this review
As with any intervention, the best intent is not the same as high-
quality evidence when considering the safety and effectiveness
of that intervention. We are faced here with an emerging prac-
tice of antenatal breast milk expression and storage in guide-
lines that do not cite evidence from a systematic review of ran-
domised controlled trials (for example, Ballarat Health Services
2010; Capital & Coast District Health Board 2012; Cox 2010;
LaLeche League Great Britain 2008; LaLeche League Great Britain
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2010; Ramsay Health Care 2011; Sandwell & West Birmingham
Hospitals 2012). The theoretical potential for benefit to the infant
and the possibility of concerns about timing of onset of labour
and of nursery admission for neonatal hypoglycaemia (as noted in
small observational studies), mandate the need for rigorous evalu-
ation of the evidence of the safety and efficacy of antenatal breast
milk expression by women with diabetes in pregnancy to improve
the outcomes for their infants. The findings of this systematic re-
view will also have the potential to impact upon successful breast-
feeding, that may reduce the risk for the mother (if she experi-
enced gestational diabetes in the index pregnancy) and the infant,
of developing diabetes later in life.
O B J E C T I V E S
To evaluate the benefits and harms of the expression and storage
of breast milk during late pregnancy by women with diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, quasi-randomised trials and cluster-
randomised trials that compare antenatal breast milk expressing
compared with not expressing. Cross-over trials are unlikely to
be appropriate for this research question and will therefore be
excluded. We also plan to exclude studies that are only reported
in abstract form, if they are identified in future updates of this
review.
Types of participants
Pregnant women with diabetes (pre-existing or gestational) with
a singleton pregnancy and their infants.
Types of interventions
Antenatal breast milk expressing, with or without storage of
colostrum for later use, compared with not expressing.
Types of outcome measures
Primary outcomes
1. Spontaneous onset of established labour prior to 37 weeks’
gestation.
2. Exclusive feeding with breast milk during the period of
hospital-based care following birth.
3. Number of episodes of low blood glucose.




1. Breast/nipple discomfort in late pregnancy.
2. Commenced breastfeeding or milk expression following
birth.
3. Women’s satisfaction with breastfeeding.
Infant
1. Gestational age at birth.
2. Duration of low blood glucose episode(s). Administration
of intravenous dextrose.
3. Exclusive feeding with breast milk within 24 hours of
discharge from hospital-based care.
4. Any feeding with breast milk within 24 hours of discharge
from hospital-based care.
5. Exclusive feeding with breast milk at three and six months.
6. Any feeding with breast milk at three and six months.
7. Economic costs (as defined by trial author).
Other outcomes/considerations
We will also consider the following in the expressing group.
1. Women’s views about antenatal breast milk expression.
2. Uterine contractions during or after antenatal breast milk
expression.
3. Maternal hypoglycaemia following antenatal breast milk
expression.
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (30
June 2014).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
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1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors (C East andWDolan) independently assessed
for inclusion all the potential studies we identified as a result of the
search strategy. We planned to resolve any disagreement through
discussion or, if required, consult a third person.
We did not identify any studies for inclusion. Methods of data
collection and analysis to be used in future updates of this review
are provided in Appendix 1.
R E S U L T S
Description of studies
Results of the search
The search of the Cochrane Pregnancy and Childbirth Group’s
Trials Register retrieved two reports. One described observational
data collected by Forster 2011a, that informed the design of the
second report, Forster 2011b The DAME Study, which is the
clinical trial registration of an ongoing randomised controlled trial
in Australia (see Figure 1 and Characteristics of ongoing studies).
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Figure 1. Study flow diagram.
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Included studies
No studies were included.
Excluded studies
One study addressed a number of the outcomes of interest, but
was an observational study (Forster 2011a). See Characteristics of
excluded studies.
Risk of bias in included studies
No studies met the eligibility criteria for inclusion in this review.
Effects of interventions
There are no included studies in this review.
D I S C U S S I O N
Summary of main results
The search strategy yielded no published studies that met the in-
clusion criteria. One study is currently underway (Forster 2011b).
Some details of this study design are provided in Characteristics
of ongoing studies.
The historical practices of preparation of the breasts, including
nipple rolling and expressing colostrum during pregnancy, with
the aim of improving breastfeeding success and minimising post-
natal trauma and engorgement have, in the main, been discon-
tinued, following no evidence of effect and recommendations not
to teach this practice, as discussed in the comprehensive literature
review of these practices by Chapman 2013b. The emergence of
the concept of expressing colostrum antenatally and storing (freez-
ing) this for postnatal use, seems a logical progression of the use of
nature (colostrum) and science/technology (storage, in countries
were this is available). This option may seem to be particularly
useful for those babies who are susceptible to neonatal hypogly-
caemia, such as those born to women with diabetes (Clay 2005;
Cox 2010). As for any new concepts, the practice of antenatal
breastmilk expression for this purpose requires rigorous evaluation
prior to widespread introduction. The one study that is currently
in progress (Forster 2011b) may contribute data to that end.
Overall completeness and applicability of
evidence
The comprehensive search strategy identified a range of published
and unpublished material, with evidence of only the one ongoing
study.
Potential biases in the review process
No evidence of bias was identified in the systematic searches for
published and unpublished studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antenatal breast milk expression and storage practices, evident in
online consumer resources and some hospital guidelines, would
appear to be a logical flow-on from the known benefits of prevent-
ing neonatal hypoglycaemia through early breastfeeding of babies
born to women with diabetes in pregnancy, as well as improving
breastfeeding success. However, they also need to be viewed by
childbearing women and their carers in the context of the lack
of high-quality evidence of their safety and efficacy, particularly
in terms of the as yet unconfirmed potential for earlier birth and
nursery admission at or after 36 weeks’ of pregnancy.
Implications for research
The theoretical potential for benefit to the infant and the possibil-
ity of concerns about timing of onset of labour and of nursery ad-
mission for neonatal hypoglycaemia, albeit beyond 36weeks’ com-
pleted weeks of gestation (as noted in small observational studies),
mandate the need for a rigorous evaluation of the evidence of the
safety and efficacy of antenatal breast milk expression in women
with diabetes in pregnancy. This would take the form of one or
more randomised trials addressing the safety and effectiveness of
antenatal breast milk expression by women with diabetes that aim
to improve infant outcomes. Outcomes of interest may include
those considered in this review.
A C K N OW L E D G E M E N T S
As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Forster 2011a This observational studywas conducted to determine the feasibility of a planned randomised controlled trial. Women
with pre-existing or gestational diabetes (requiring insulin) who planned to breastfeed were enrolled. The women
were encouraged to express and store colostrum from 36weeks’ gestation. Fetal heart ratemonitoring was undertaken
after expressing for the first time. There was no evidence of fetal compromise. The median volume of colostrum
obtained as 39.6 mL. Outcomes for this group were compared with those from a retrospective audit of 89 women
with diabetes who had not expressed during pregnancy
Characteristics of ongoing studies [ordered by study ID]
Forster 2011b
Trial name or title Diabetes and antenatal milk expressing (DAME): a randomised controlled trial
Methods Randomised controlled trial.
Participants Women with diabetes in pregnancy who are intending to breastfeed
Interventions Intervention: women with diabetes in pregnancy who are intending to breastfeed will commence twice daily
antenatal milk expressing (and milk storage) from 36 weeks’ gestation until birth
Standard care: women with diabetes in pregnancy who are intending to breastfeed will receive usual care. In
usual care, women are not advised to commence expressing breast milk antenatally
Outcomes The proportion of infants:
• requiring admission to the special or intensive care nursery;
• receiving exclusive breast milk at three months of age;
• receiving exclusive breast milk during the hospital stay after birth.
The mean gestation at birth.
Starting date 1 May 2011.
Contact information anita.moorhead@latrobe.edu.au
Notes Two authors of the Cochrane Review, Della Forster and Christine East, are also investigators on the DAME
trial. (See Declarations of interest)
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Methods of data collection and analysis to be used in future updates of this review
Data collection and analysis
Selection of studies
At least two review authors (C East and W Dolan or D Forster) will independently assess for inclusion all the potential studies we
identify as a result of the search strategy. A fourth co-author (to be appointed) will assist W Dolan in assessing for inclusion the Forster
2011b when it is considered in future updates of this review (see Declarations of interest).
We will resolve any disagreement through discussion or, if required, we will consult a third person.
Data extraction and management
We will design a form to extract data. For eligible studies, at least two review authors (CE and WD, or DF) will extract the data using
the agreed form. We will resolve discrepancies through discussion or, if required, we will consult a third person. We will enter data into
Review Manager software (RevMan 2014) and check for accuracy.
When information regarding any of the above is unclear, we will attempt to contact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors (CE and WD or DF) will independently assess risk of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). We will resolve any disagreement by discussion or by involving a third
assessor.
(1) Random sequence generation (checking for possible selection bias)
We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We will describe for each included study the method used to conceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);
• unclear risk of bias.
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(3.1) Blinding of participants and personnel (checking for possible performance bias)
We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which
intervention a participant received. We will consider that studies are at low risk of bias if they were blinded, or if we judge that the lack
of blinding would be unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible detection bias)
We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a
participant received. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing
data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial
authors, we will re-include missing data in the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial
departure of intervention received from that assigned at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-specified outcomes and all expected outcomes of interest to the review
have been reported);
• high risk of bias (where not all the study’s pre-specified outcomes have been reported; one or more reported primary outcomes
were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We will describe for each included study any important concerns we have about other possible sources of bias.
We will assess whether each study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wewill make explicit judgements about whether studies are at high risk of bias, according to the criteria given in theHandbook (Higgins
2011). With reference to (1) to (6) above, we will assess the likely magnitude and direction of the bias and whether we consider it is
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likely to impact on the findings. We will explore the impact of the level of bias through undertaking sensitivity analyses - see Sensitivity
analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk ratio with 95% confidence intervals.
Continuous data
For continuous data, we will use the mean difference if outcomes are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials in the analyses along with individually-randomised trials. We will adjust their sample sizes
using the methods described in the Handbook using an estimate of the intracluster correlation co-efficient (ICC) derived from the
trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this
and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and
individually-randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results
from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Cross-over trials
As it unlikely that cross-over designs will be appropriate for this research question, we will exclude them.
Other unit of analysis issues
We will exclude multiple pregnancies in order to avoid the related issues with the unit of analysis.
Dealing with missing data
For included studies, we will note levels of attrition. We will explore the impact of including studies with high levels of missing data in
the overall assessment of treatment effect by using sensitivity analysis.
For all outcomes, we will carry out analyses, as far as possible, on an intention-to-treat basis, i.e. we will attempt to include all participants
randomised to each group in the analyses, and all participants will be analysed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention. The denominator for each outcome in each trial will be the number randomised
minus any participants whose outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We will regard heterogeneity as
substantial if the I² is greater than 30% and either the T² is greater than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
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Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will investigate reporting biases (such as publication bias) using funnel plots.
We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses
to investigate it.
Data synthesis
We will carry out statistical analysis using the Review Manager software (RevMan 2014). We will use fixed-effect meta-analysis for
combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are
examining the same intervention, and the trials’ populations and methods are judged sufficiently similar. If there is clinical heterogeneity
sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we
will use random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials is considered clinically
meaningful. The random-effects summary will be treated as the average range of possible treatment effects and we will discuss the
clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not
combine trials.
If we use random-effects analyses, the results will be presented as the average treatment effect with 95% confidence intervals, and the
estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether
an overall summary is meaningful, and if it is, use random-effects analysis to produce it.
We plan to carry out the following subgroup analysis.
• Type of diabetes: gestational versus Type 1 versus Type 2.
The following outcome will be used in subgroup analysis.
• Exclusive breastfeeding during the period of hospital-based care following birth.
We will assess subgroup differences by interaction tests available within RevMan (RevMan 2014).We will report the results of subgroup
analyses quoting the χ2 statistic and P value, and the interaction test I² value.
Sensitivity analysis
We will carry out sensitivity analysis to explore the effects of trial quality assessed by allocation concealment and other risk of bias
components, by omitting studies rated as ’high risk of bias’ for these components. This will be restricted to the primary outcomes.
C O N T R I B U T I O N S O F A U T H O R S
Christine East compiled the protocol and review and is the guarantor for the review.
Willie Dolan and Della Forster contributed to the protocol and review content and reviewed them prior to submission.
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D E C L A R A T I O N S O F I N T E R E S T
Willie J Dolan: none known.
Della Forster is the Principal Investigator and Christine East is a co-investigator on a study that directly addresses this issue and that,
when completed, would be included in this systematic review (Forster 2011b). All decisions relating to inclusion of that trial (assessment
for inclusion, trial quality and data extraction) will be carried out by Willie Dolan and by an additional co-author (yet to be named)
of this review who are not directly involved in the trial.
S O U R C E S O F S U P P O R T
Internal sources
• Monash Health, Australia.
Women’s and Children’s Program
• Monash University, Australia.
School of Nursing and Midwifery
• Royal Women’s Hospital, Australia.
• La Trobe University, Australia.
Mother and Child Health Research
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
A number of changes have been made in this review, compared to protocol, on the basis of greater clarity for the reader and on the
recommendations of reviewers.
The Background has been extensively expanded in the review.
The followingTypes of outcomemeasures are those that were edited or added either following further discussions between the authorship
about the importance and implications of outcomes, or at the suggestion of the reviewers.
Primary outcomes
#1 Spontaneous onset of established labour prior to 37 weeks’ gestation.
• This was a secondary outcome in the protocol. The authors have had further discussions and consider that if antenatal breast
milk expression contributes in any way to earlier than expected birth, albeit close to the time of being term, then this may not serve
the babies well, as near-term babies require more care than their term counterparts.
#2 Exclusive feeding with breast milk during the period of hospital-based care following birth.
• This was edited to capture infant feeding with expressed breast milk, rather than potentially interpreting the outcomes as only
feeding from the breast directly. Several of the secondary outcomes have also been edited to reflect this.
#3 & #4 in the protocol, Duration of low blood glucose episode(s) and Administration of intravenous dextrose.
• The authors have discussed the priorities of the limited number of primary outcomes (3 or 4) in Cochrane systematic reviews.
These two outcomes have now been made secondary outcomes. Given that the main goal of antenatal breast milk expression is to
improve infant outcomes, this can be better reflected in the need to care for these babies in the special care nursery or intensive care
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nursery, where the duration of low blood glucose episodes will influence the need for intravenous dextrose. Hence, the revised
outcome #4 is as follows:
Revised #4 Admission to special care nursery or neonatal intensive care nursery.
Secondary outcomes
Maternal
#1 in the protocol, Uterine contractions during or after antenatal breast milk expression, has been moved to “Other outcomes/considera-
tions”, as this will only apply to the group of women who are expressing.
#1 in the review is now, Breast/nipple discomfort in late pregnancy.
• This has been added at the suggestion of the reviewers.
#5 Commenced breastfeeding or milk expression following birth.
• This has been added at the suggestion of the reviewers.
Infant
• These changes are described under “Primary outcomes”, above.
Other outcomes/considerations
This has now been edited to reflect that certain outcomes may only be noted in the group of women who are expressing antenatally.
We will also consider the following in the expressing group.
#2 Uterine contractions during or after antenatal breast milk expression.
• as described above
#3 Maternal hypoglycaemia following antenatal breast milk expression.
• The authors have added this as an important consideration for the mother in this group.
The Types of participants and Types of interventions have undergone minor wording changes to clarify the intent of the protocol
wording.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Colostrum; ∗Diabetes Mellitus; ∗Pregnancy in Diabetics; Breast Milk Expression [∗adverse effects]; Hypoglycemia [∗therapy]; Infant,
Newborn, Diseases [∗therapy]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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